On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 10.42% from the last session, before settling in for the closing price of $7.10. Price fluctuations for RXRX have ranged from $5.03 to $15.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 132.77% over the last five years. Company’s average yearly earnings per share was noted 1.97% at the time writing. With a float of $223.17 million, this company’s outstanding shares have now reached $226.26 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 22.15%, while institutional ownership is 79.40%. The most recent insider transaction that took place on Oct 29 ’24, was worth 76,926. In this transaction Director of this company sold 11,447 shares at a rate of $6.72, taking the stock ownership to the 7,077,560 shares. Before that another transaction happened on Oct 29 ’24, when Company’s Director proposed sale 11,447 for $6.72, making the entire transaction worth $76,926.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 1.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.68 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Analysing the last 5-days average volume posted by the [Recursion Pharmaceuticals Inc, RXRX], we can find that recorded value of 7.95 million was better than the volume posted last year of 5.72 million. As of the previous 9 days, the stock’s Stochastic %D was 80.77%. Additionally, its Average True Range was 0.43.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 49.12%, which indicates a significant decrease from 71.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.87% in the past 14 days, which was lower than the 74.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.58, while its 200-day Moving Average is $8.45. Now, the first resistance to watch is $8.48. This is followed by the second major resistance level at $9.11. The third major resistance level sits at $9.74. If the price goes on to break the first support level at $7.22, it is likely to go to the next support level at $6.59. Should the price break the second support level, the third support level stands at $5.96.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 281,109K shares outstanding in the company with a market cap of 2.30 billion. Presently, the company’s annual sales total 44,580 K according to its annual income of -328,070 K. Last quarter, the company’s sales amounted to 14,420 K and its income totaled -97,540 K.
